NICE amends ranibizumab guidance

NICE has overturned its original decision to reject the VEGF-targeting antibody ranibizumab (Lucentis) in the treatment of diabetic macular oedema.

Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY
Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY

In a review of its 2011 guidance, NICE has ruled that ranibizumab can be considered for the treatment of visual impairment due to diabetic macular oedema, providing the eye has a central retinal thickness of 400 micrometers or more at the start of treatment.

The NICE recommendations are made on the proviso that the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

In addition to the revised patient access scheme, the decision was based on an updated clinical analysis of ranibizumab submitted by the manufacturer.

NICE guidance on ranibizumab in diabetic macular oedema

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

News in brief - September 2013

News in brief - September 2013

Other new launches, licence changes and updates relevant...

NICE recommends aflibercept for AMD

NICE recommends aflibercept for AMD

New guidance from NICE approves the use of aflibercept...

Iluvien: intravitreal corticosteroid implant for diabetic macular oedema

Iluvien: intravitreal corticosteroid implant for diabetic macular oedema

Alimera has launched an intravitreal implant containing...

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab (Lucentis) can now be prescribed in the...

Lucentis approved for visual impairment due to retinal vein occlusion


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more